different from that measured in historical controls who received 600 mg/m 2 of BCNU. Combined hospital and physician charges for patients treated at the University Breast cancer patients with more than three involved axillary lymph have a high likelihood of relapse after of Colorado decreased from a mean of $125 845 for the first four patients to $77 126 for the final seven patients. adjuvant therapy. Early results of administration of high-dose chemotherapy (HDCT) and autologous periWe conclude that HDCT with autologous PBPC can be administered with acceptable safety to patients with pripheral blood progenitor cells (PBPC) to patients with primary breast cancer and у у у10 involved axillary nodes mary breast cancer involving 4-9 axillary lymph nodes. An ongoing, prospective randomized trial is evaluating have been encouraging. We performed a multicenter trial to determine whether HDCT could be safely the efficacy of HDCT for this patient group. Keywords: stem cell transplantation; dose-intensive administered to patients with primary breast cancer involving 4-9 axillary lymph nodes. Fifty-four patients therapy; breast cancer with stage II or III breast cancer and 4---9 involved axillary lymph nodes received doxorubicin-based induction chemotherapy, followed by high-dose cyclophosphamide
nodes with reasonable safety, since the 5-year actuarial disPeripheral blood progenitor cell (PBPC) collection and storage ease-free survival for this group may exceed 50% with conventional dose chemotherapy. The results of HDCT for After recovery of the peripheral blood counts following the patients with primary breast cancer and 4-9 involved final cycle of induction chemotherapy, patients were treated axillary nodes are reported.
with hematopoietic growth factors to mobilize PBPC. The first 15 patients received granulocyte-macrophage colonystimulating factor (GM-CSF, Leukine; Immunex, Seattle, WA, USA) at a dose of 250 g/m 2 subcutaneously for 8 Materials and methods days. The remaining 37 patients received granulocyte colony-stimulating factor (G-CSF, Neupogen; Amgen, Thousand Oaks, CA, USA) at a dose of 5 g/kg/day subcuPatient selection taneously for 8 days. The change in hematopoietic growth factor was prompted by frequent fevers as well as slower Patients referred to the University of Colorado Health engraftment for patients who received GM-CSF (compared Sciences Center, the Cleveland Clinic Foundation and the with historical controls at the University of Colorado University of Arizona Medical Center between August treated with G-CSF). On days 5, 6, 7 and 8 of the hemato-1992 and October 1995 with newly diagnosed primary poietic growth factor, patients underwent leukapheresis. breast cancer (T1-3, N1-2, M0) with more than three but Growth factors were generously supplied by the manufacfewer than 10 involved axillary lymph nodes were eligible turers. PBPC were collected using a Cobe Spectra apheresis for this clinical trial. All patients were staged with CT scans machine (Cobe, Lakewood, CO, USA). Approximately 9 l of the head, chest, abdomen, and pelvis; bone scan; and of blood was processed for 3 h through a double-or triplebilateral posterior iliac crest marrow biopsies. Furthermore, lumen right atrial catheter. A final volume of approximately all patients were required to have satisfactory end-organ 200 ml was collected on each of 4 leukapheresis days. The function as demonstrated by pulmonary function tests required nucleated cell count for each patient's total (forced expiratory volume and diffusing capacity у60% of (cumulative) PBPC graft was 4 × 10 8 /kg. Additional leupredicted), radionuclide ventriculography (ejection fraction kaphereses were permitted when necessary to obtain suf-у45% at rest, with exercise augmentation), 24-h urine colficient cells. The PBPC collections were suspended in lection for creatinine clearance (у60 ml/min), AST and 72.5% tissue culture medium 199 (TC-199), 7.5% dimethyl total bilirubin р1.5 × the upper limit of normal for the sulfoxide and 20% autologous plasma, and cryopreserved patient's referring institution, and be seronegative for the using a controlled-rate freezing method, 10 and stored at human immunodeficiency virus. Patients who had been −196°C. treated with chemotherapy, hormonal therapy or radiotherapy for primary breast cancer, and patients with previous or concomitant malignancies other than in situ carciHigh-dose chemotherapy noma of the cervix, non-melanotic skin cancer or synchronous primary breast cancer were ineligible for this High-dose cyclophosphamide, cisplatin and BCNU were program. This study was approved by the Institutional administered according to the schedule in Figure 1 . CycloReview Boards of each participating institution. All patients phosphamide was infused over 1 h on 3 consecutive days gave written informed consent prior to the start of any at a dose of 1.875 g/m 2 /day. Cisplatin was administered by treatment.
72 h infusion at a total dose of 165 mg/m 2 , starting at the beginning of the first cyclophosphamide infusion. At the completion of the cisplatin infusion, BCNU was administered at a dose of 450 mg/m 2 over 90 min. This represents a Conventional-dose adjuvant therapy 25% reduction in the dose of BCNU, relative to the regimen reported by Peters et al. 3 The reduction in BCNU dose was All patients received conventional-dose chemotherapy made in an effort to reduce the risk of late pulmonary within 8 weeks of primary surgery. The first four patients drug toxicity.
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were treated at the University of Colorado and received three 21-day cycles of doxorubicin (90 mg/m 2 on day 3) plus 5-fluorouracil (250 mg/m 2 continuous infusion on days 1-3). When this study expanded to the Cleveland Clinic and the University of Arizona, the induction regimen was modified to four cycles of doxorubicin (60 mg/m 2 ) and cyclophosphamide (1200 mg/m 2 ) on day 1 of each 21-day cycle. The doxorubicin/cyclophosphamide regimen was chosen because it was a regimen being employed in an ongoing NSABP trial, 9 which would provide 'historical controls'. Fifty patients received this induction regimen. Two patients did not go on to receive HDCT. One patient relapsed during the final cycle of induction chemotherapy HDCT. Both patients are included in the survival analysis.
Supportive care
compartment model with constant intravenous input and first order output, was used. The area under the curve All patients received continuous bladder irrigation starting (AUC) for BCNU concentration × time for patients who 4 h prior to the first dose of cyclophosphamide and continuunderwent treatment at the University of Colorado was ing for 24 h after the final dose of cyclophosphamide.
compared with those of patients with primary breast cancer Patients were hydrated using normal saline at a minimum and 10 or more involved axillary nodes, who received rate of 250 ml/m 2 /h. All patients who received HDCT were 600 mg/m 2 (rather than 450 mg/m 2 ) of BCNU.
3 also treated with prednisone at a dose of 1 mg/kg/day starting on day −7 and ending on day −1, also in an effort to Radiation therapy prevent late pulmonary drug toxicity. Institutional guidelines were followed regarding empiric antibiotics, blood All patients were required to receive radiotherapy to the product support, treatment of febrile neutropenia and involved breast or ipsilateral chest wall and the supraclaviccriteria for discharge from the hospital. ular fossa after the completion of HDCT. A total dose of 5000 cGy was administered to the chest wall and supraclavicular nodes of patients who had a modified radical mastecReinfusion of PBPC tomy as primary surgery. For patients who had a breast Cryopreserved PBPCs were thawed and rapidly infused on conservation procedure as primary surgery, 4600 cGy was days −1, 0 and +1. Starting on the day of the first PBPC administered to the ipsilateral breast, with a 1600 cGy boost reinfusion, patients were begun on the same hematopoietic to the tumor bed. All radiotherapy was administered in 200 growth factor they received for PBPC mobilization. GMcGy daily fractions. CSF was administered at a dose of 250 g/m 2 twice a day and G-CSF was administered at a dose of 5 g/kg/day. Tamoxifen Hematopoietic growth factors were administered intravenously until the platelet count was у50 × 10 9 /l, at which All patients received tamoxifen at a dose of 20 mg per day, time subcutaneous injection was permitted. The hematopostarting approximately 6 weeks after the completion of ietic growth factors were continued until the absolute neu-HDCT. Tamoxifen is to be administered until relapse or trophil count (ANC) was у5 × 10 9 /l for 3 consecutive days. for 5 years, whichever occurs first. Myeloid engraftment was defined as the first of 2 consecutive days where the ANC was у0.5 × 10 9 /l. Platelet Statistics engraftment was defined as the first of 2 consecutive days that platelets reached or exceeded 20 × 10 9 /l without The Student's t-test was used to compare differences in the transfusion support.
number of nucleated cells collected after administration of GM-CSF or G-CSF and 2 analysis was used to compare the incidences of pulmonary toxicity between patients with Pharmacology 4-9 nodes and patients with 10 or more nodes. Survival, Blood samples for BCNU were obtained, prepared and anadisease-free survival and time to engraftment were estilyzed as previously described. 11 Briefly, high-performance mated by the method of Kaplan and Meier. 12 Time to liquid chromatography was carried out on a Waters Associengraftment was compared between patient groups using ates HPLC apparatus, consisting of a Model 712 WISP the logrank test. autosampler, Model 510 pumps, a guard precolumn and an 8 × 100-mm Nova-Pak C18 radial compression cartridge with a 4 micrometer silica packing (Waters Associates, MilResults ford, MA, USA) and a Model 490 ultraviolet detector set at a wavelength of 237 nm. The instrument was interfaced Patient characteristics (Table 1 ) using a Waters Associates SIMM module connected to a Pentium-based microcomputer equipped with Maxima 820
Fifty-four patients (53 females, one male) with primary breast cancer and 4-9 involved axillary nodes were enrolled software. Samples were eluted isocratically using a mobile phase of 55% methanol-45% water at a flow rate of on this clinical trial. Median age was 44 (range 29-55) years. Thirty-nine patients (72%) had stage II and 15 (28%) 1.5 ml/min. Retention times for BCNU and internal standard were 5.0 and 6.1 min, respectively. Standards were had stage III disease. The median numbers of involved and sampled lymph nodes were six (range 4-9) and 16 (range prepared using outdated whole blood spiked with analytical-grade BCNU (Bristol-Myers Squibb, Princeton, NJ, 6-46), respectively. Twenty-six patients (48%) had tumors which were estrogen-and progesterone-receptor positive, USA) at concentrations ranging from 0.01 to 50 g/ml and were processed identically to patient samples. A minimum eight (15%) had tumors which were estrogen receptor-positive and progesterone receptor-negative, 17 (31%) had of two quality control samples of known concentrations of BCNU were included in each chromatography session.
tumors which were estrogen-and progesterone receptornegative, and three (6%) had tumors which were estrogen BCNU concentration and sample time data were used for calculation of derived pharmacokinetic parameters, with receptor-negative and progesterone receptor-positive. Forty-seven patients (87%) underwent modified radical PCNONLIN software (Statistical Consultants, Lexington, KY, USA) and a Pentium-based microcomputer used to mastectomy and seven patients (13%) underwent breastconserving surgery with axillary dissection. perform the analyses. Model 2 from PCNONLIN, a one- 8 /kg) for those who received G-CSF (P = 0.68). which was in the mediastinum. The median number of days from the first infusion of proThirty-one patients developed febrile neutropenia. Three genitor cells to absolute neutrophil count у5 × 10 9 /l was were diagnosed with Clostridium difficile enterocolitis, 11 (range 8-15) for patients who received G-CSF and 14 which was successfully treated with intravenous metronida-(range 11-32) for patients who received GM-CSF (logrank zole in two patients and oral vancomycin in the other. Three P = 0.0001). The median number of days from the first patients developed bacteremia; two with coagulaseinfusion of progenitor cells to a platelet count of 20 × 10 9 /l negative Staphylococcus and one with Streptococcus viridwithout transfusion was 16 (range 10-42) and 25 (range ans. One patient developed myelodysplasia 809 days after 18-51), respectively, for patients receiving G-CSF and the start of HDCT. She is currently 6 months post-allo-GM-CSF (logrank P = 0.0055).
geneic marrow transplantation from an HLA-identical sibling.
Treatment-related toxicity
Four patients (8%) became refractory to platelet transSignificant treatment-related complications for all 52 fusions in the early post-transplant period and were treated patients who received HDCT are shown in Table 2 . Fifteen with intravenous immunoglobulin and/or corticosteroids. All four had been mobilized with and received GM-CSF Two patients received their entire treatment as inpatients.
a Includes one fatality.
One was a patient with type I diabetes mellitus. The second patient (UPN 432) suffered a transected subclavian vein 532 g.min/ml (range 150-2504) for patients with 10 or more nodes. These differences were not statistically sigduring right atrial catheter placement, as noted above.
For the 37 patients discharged shortly after HDCT, the nificant (P = 0.113). median duration of first hospitalization was 7 days (range 6-14 days). Twenty patients were readmitted to the hospital Economic analysis for a median hospital stay of 1 day (range 1-16 days). The primary reason for readmission was febrile neutropenia in Total hospital and physician charges for HDCT and autologous PBPC support were available for the 37 University 15 patients, volume depletion with severe nausea and vomiting in one patient, and refractory thrombocytopenia in of Colorado patients who were discharged from the hospital shortly after completing high-dose chemotherapy. The four patients. mean total charge was $99 695 (range $68 736-$176 724). Average costs decreased substantially over time for patients Survival and relapse treated on this study (Figure 3) . One patient died of pulmonary toxicity 24 months after transplant without evidence of breast cancer. One patient relapsed during the final cycle of induction chemotherapy Discussion (and did not receive HDCT) and nine patients relapsed after completing HDCT. Seven of these 10 patients have died.
This feasibility study was conducted to determine whether HDCT requiring hematopoietic progenitor cell support Five of the 10 patients had hormone receptor-negative disease and six had between seven and nine involved nodes.
could be safely administered to patients with primary breast cancer who had more than three but fewer than 10 involved One of the patients relapsed locally prior to the start of chest wall radiation.
axillary lymph nodes. Although the administration of hematopoietic growth factors have made HDCT less toxic, Peters Forty-three patients are alive without evidence of recurrent breast cancer (including the one patient who developed et al 6 reported in 1993 that 12% of primary breast cancer patients with 10 or more involved nodes treated with HDCT myelodysplasia) at a median follow-up of 947 days (range 661-1730 days) after the start of induction chemotherapy.
died of treatment-related complications. We felt that a treatment-related mortality of 12% in the 4-9 node patient Actuarial survival and disease-free survival are 84 and 71%, respectively (Figure 2) . population would have been unacceptable. It was therefore necessary to conduct a feasibility study to demonstrate that HDCT was safe in 4-9 node patients.
Pharmacokinetics
There is a clear rationale for evaluating the role of HDCT in this patient group. First, actuarial 5-year disease-free Plasma area under the curve for BCNU concentration × time (AUC BCNU ) was determined in patients treated at the survival in most studies of conventional-dose adjuvant chemotherapy is in the range of 50-60%. 13, 14 Over time, University of Colorado and compared with those of patients with primary breast cancer and у10 axillary lymph nodes disease-free survival decreases further. 14 Second, there are numerous clinical and preclinical models demonstrating a treated at the same institution. These patients differed in the dose of BCNU administered (450 mg/m 2 for patients dose-response effect in breast cancer, with relapse-free survival correlating with dose intensity. [15] [16] [17] [18] [19] [20] [21] [22] [23] Finally, sigwith 4-9 nodes and 600 mg/m 2 for у10 nodes), although the rate of administration (5 mg/m 2 /min) was the same. The nificant improvement has been made in the supportive care of patients receiving high-dose therapy, particularly with mean plasma AUC BCNU was 400 g.min/ml (range 82-1255) for patients with 4-9 involved nodes and the use of peripheral blood-derived hematopoietic progeni- tors and colony-stimulating agents, 24-28 resulting in a $77 126 for the last seven patients, who were treated between July and September 1995. These charges included reduction in treatment-related morbidity and mortality.
Fifty-four patients received doxorubicin-based induction collection and storage of peripheral blood progenitor cells, professional fees, hospital feeds for the initial hospitalizchemotherapy, with 52 patients consolidated with highdose cyclophosphamide, cisplatin and BCNU, with autologation and for readmissions to the hospital. They did not include accommodation or food charges for the patients or ous PBPC support. There was one treatment-related death. With the exception of time to engraftment, there were no their families, once they had been discharged from the hospital, if they did not reside near the University of Colorado significant outcome differences (febrile neutropenia, readmission to hospital or infection) between patients who Health Sciences Center. Staging evaluations prior to transplant were done by the referring physician and were not received GM-CSF and G-CSF (data not shown). Similar data have been reported elsewhere. 29 included in the charges. Furthermore, CT scans, bone scans, and bone marrow biopsies were not performed at the comPulmonary toxicity occurred in 15 (29%) patients, including one fatal case, despite the 25% reduction in pletion of their transplant course. Finally, post-transplant radiotherapy was not included in these charges. We attri-BCNU dose from 600 mg/m 2 to 450 mg/m 2 and corticosteroid administration during HDCT. This was not substanbute the decrease in cost to fewer complications requiring prolonged initial hospitalizations or readmission (three of tially different from what has been reported with administration of 600 mg/m 2 and no corticosteroids at Duke the first four patients developed refractory thrombocytopenia) and to fewer patients being routinely readmitted University or at the University of Colorado. 11 Furthermore, the mean plasma AUC BCNU was not significantly different for febrile neutropenia. Whether HDCT is the best way to treat primary breast for patients who received 450 mg/m 2 compared with those who received 600 mg/m 2 . The patients were treated with cancer patients with 4-9 nodes cannot as yet be determined.
Of the nine patients who relapsed after HDCT, seven did corticosteroids and 14 of the 15 affected patients had prompt improvement. The patient who did not recover so less than 2 years after the start of induction therapy. What is clear is that this approach is safe and preliminary developed pulmonary toxicity that was not immediately diagnosed. Treatment with corticosteroids was delayed, she data suggest that it is as effective as conventional therapy alone. It is important to recognize that high-dose chemodeveloped chronic obstructive and restrictive pulmonary disease requiring supplemental oxygen and ultimately died.
therapy usually requires at least a brief hospital stay, increased risk of febrile neutropenia, and may increase risk It cannot be overstated that vigilant attention to pulmonary complaints is essential. Chronic pulmonary dysfunction of second malignancies in survivors. Based on these data, a prospective randomized trial has after BCNU-containing HDCT can be prevented by prompt evaluation of pulmonary function and institution of corticobeen initiated in the Cooperative Breast Cancer Intergroup. This trial compares intensive sequential chemotherapy consteroids.
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Three patients on this study also developed cathetersisting of doxorubicin, paclitaxel and cyclophosphamide, using G-CSF support, 30 with standard-dose doxorubicin and related complications, including one patient who suffered a laceration of the subclavian vein with a resultant hemocyclophosphamide followed by HDCT using either cyclophosphamide, cisplatin and carmustine (STAMP I) 3 or thorax and required emergency surgery to stop bleeding. While these patients recovered without difficulty, any of cyclophosphamide, carboplatin, and thiotepa (STAMP V) 5 and reinfusion of autologous hematopoietic cells. Five these catheter-related complications could have been lifethreatening. hundred patients will be accrued to each arm. One patient developed myelodysplasia approximately 2.5 years after receiving HDCT. She is alive without breast
